Development

Combining existing medicines to target aging

Rejuvenate Biomed closes in on €9 million funding round for human trials of sarcopenia-targeted combined drug. Already well-known for its beer and bureaucracy to its...

Insilico opens Pandomics box for AI target discovery

Insilico announces Pandomics, an AI-powered hypothesis generation engine that interprets OMICS and text-based data for the discovery and analysis of new therapeutic targets. Insilico is...

Psychobiome: trusting your gut for Longevity

Scientists studying how the microbiome affects our mood aim to develop gut microbiome-modulating formulations to treat depression and other brain diseases. Recent work from Katya...

New immune aging drug brings Longevity and C19 hope

Phase 2-ready drug can treat and reverse immune aging, BioAge claims. BioAge Labs' in-licensed clinical-stage therapy has potential for treating immune aging in older patients...

Longevity trials: time to change the approach?

Leading academic says high profile trial failures should drive changes in how we approach trials for drugs that target aging. Following the recent clinical trial...

The metformin debate swings both ways

Research on metformin is not at the beginning of the end, but it is, perhaps, at the end of the beginning. The drug giveth and...

Leading academic sees “great promise” in longevity supplements

Buck professor Brian Kennedy talks about AKG and the potential for supplements to deliver real anti-aging benefits. Following Tuesday’s news from the Buck Institute about...

ARDD 2020: Exclusive interview with Calico’s PI

Calico's Adam Freund tells us about using a network approach to aging – and that PAPP-A does preach. It's ARDD week; the annual Aging Research &...

AKG study first to show “dramatically compressed” morbidity in mammals

The Buck's new peer-reviewed study of alpha-ketoglutarate shows a significant reduction in frailty in older mice, resulting in compression of late-life morbidity. The Buck Institute...

Relation-Mila collaboration wins $1.3m Gates Foundation Award to fight COVID-19

Relation receives $1.3m grant funding from the Gates Foundation to identify COVID-19 therapeutic candidates. Relation Therapeutics (a Juvenescence-incubated company) and Mila, the Montreal-based AI research...

Healthy aging – it’s still all about diet and exercise. For now

As Healthy Aging Month arrives, Dr Thomas Rando shares his views on progress in Longevity science. For the past two decades, September has been celebrated...

$2m Longevity boost for rapamycin Alzheimer’s study

Rapamycin human clinical trial aims to make progress on Alzheimer's therapy. A new $2m grant will enable a clinical trial to examine the effects of...

ARDD 2020: Addressing the challenges in drug discovery

We speak to the co-founder of Molecule about building a unique marketplace for early stage therapeutic development. Next week (September 1 - 4), the annual...

Aging as a new therapeutic frontier: a call for collaboration

Could looking at aging in a new way be key to the development of therapeutics for a wide range of age-related disorders? Authors of...

Senolytics research shows Longevity progress

Senolytic research in humans may be in its infancy, but there is reason for cautious optimism. Last week we reported on biotech company UNITY's decision...

Elysium publishes positive results from two studies for Basis

Encouraging news from Elysium Health illustrates that the Longevity supplements market is building clinical and commercial traction. In December 2019, Elysium announced a $40m Series...

Taking NAD+ to the next level

Nuchido’s systems pharmacology approach yields NAD+ supplement that claims to boost levels by 242%!    A new player in the NAD+ supplement market has arrived...

UNITY cuts lead program after clinical trial fail

Company to focus on ophthalmologic and neurologic programs as Phase 2 knee osteoarthritis clinical study fails to meet primary endpoint. Senolytic therapy developer UNITY...

Juvenescence (2): “It’s all about prevention, and that’s incredibly disruptive”

Juvenescence's Greg Bailey on democratising healthcare, paradigm shifts and disruptive technologies. Yesterday we published the first part of our interview with Greg Bailey, CEO of...

New blood test diagnoses Alzheimer’s Disease decades before symptoms

A new blood test could diagnose Alzheimer’s Disease 20 years before symptoms appear, paving the way for breakthroughs in research and treatment. It's hoped the...

Latest articles

Epigenetic regulation of protein homeostasis following DNA damage

Recent study identifies critical regulator of protein biosynthesis recovery and homeostasis required for Longevity. Unresolved DNA damage caused by intrinsic and environmental factors accumulates during...

Deep Longevity and Longenesis collaborate to clock aging

Start the clock to stop the clock – centralised data will aid Longevity research.  Deep Longevity, which engages in the development of explainable AI systems...

Big Brother approach to accelerate preclinical studies

Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

Astellas to acquire iota Biosciences

Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal. Last year's R&D...